Controlling type i errors for two-stage bioequivalence study designs

Clinical Research and Regulatory Affairs

Volumn 28, Issue 4, 2011, Pages 100-105

  Fuglsang, Anders ^a  

^a NONE   (Germany)

Author keywords

Bioequivalence; Ethics; Sequential design; Trial simulation; Type I error

Indexed keywords

GENERIC DRUG;

ANALYTICAL ERROR; ARTICLE; BIOEQUIVALENCE; DRUG DETERMINATION; DRUG FORMULATION; SIMULATION;

EID: 82555173008     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.3109/10601333.2011.631547     Document Type: Article

References (16)

1. Chow SC, Liu JP. 2009. Design and analysis of bioavailability and bioequivalence studies. 3rd ed.: CRC Press.
2. Committee for Human Medicinal Products. Guideline on the investigation of bioequivalence. 2010. Available online at: Http:// www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf, accessed 19 July 2011.
3. US Food & Drug Administration. Bioavailability and bioequivalence studies for orally administered drug products - General considerations. 2003. Available online at: Http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm070124.pdf, accessed 19 July 2011.
4. UK Medicines and Healthcare Products Regulatory Agency. Asssessment report PL 17507/0053. 2006. Available online at: Http://www.mhra.gov.uk/home/ groups/l-unit1/documents/ websiteresources/con013949.pdf, accessed 19 July 2011.
5. UK Medicines and Healthcare Products Regulatory Agency. Asssessment report UK/H/1833/01/DC. 2011. Available online at: Http://www.mhra.gov.uk/home/ groups/par/documents/website resources/con114440.pdf, accessed 19 July 2011.
6. UK Medicines and Healthcare Products Regulatory Agency. Asssessment report UK/H/1066/01-03/DC. 2008. Available online at: Http://www.mhra.gov.uk/ home/groups/pl-a/documents/website resources/con018234.pdf, accessed 19 July 2011.
7. UK Medicines and Healthcare Products Regulatory Agency. Asssessment report P 33155/0001 & 33155/0003. 2010. Available online at: Http://www.mhra.gov.uk/home/groups/par/documents/ websiteresources/con114440. pdf, accessed 19 July 2011.
8. Medicines Evaluation Board in the Netherlands. Assessment report NL/H/1209/01-03/. 2011. Available online at: Http://db.cbg-meb. nl/mri/par/nlh-1209-001-002-003.pdf, accessed 19 July 2011.
9. Medicines Evaluation Board in the Netherlands. Assessment report NL/H/317/001/E/001. 2010. Available online at: Http:// www.cbg-meb.nl/NR/ rdonlyres/CAF4CA92-E201-4F2F-83E4- B90444FE85C7/0/PARLoratadineSandoz10-317-E- 15, accessed 19 July 2011.
10. Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA. Sequential design approaches for bioequivalence studies with crossover designs. Pharm Stat 2008;7:245-262.
11. Committee for Human Medicinal Products. 2009. Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in adults and for use in the treatment of asthma in children and adolescent. Available online at: Http://www.ema.europa.eu/docs/en-GB/ document-library/ Scientific-guideline/2010/01/WC500070039. pdf, accessed 19 July 2011.
12. Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House KW, Ortega HG. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: Implications for establishing bioequivalence of inhaled products. Clin Ther 2009;21:370-385.
13. Montague TH, Potvin D, Diliberti CE, Hauck WW, Parr AF, Schuirmann DJ. Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'. Pharm Stat 2011;7: DOI: 10.1002/pst.483.
14. Matsumoto M, Nishimura T. Mersenne twister: A 623-dimensionally equidistributed uniform pseudo-random number generator. ACM Trans Model Comp Simul 1998;8:3-30.
15. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1997;64:191-199. 16. Cui L, Hung MJ, Wang S-J. Modification of sample size in group sequential clinical trials. Biometrics 1999;55:853-857.
16. Cui L, Hung MJ, Wang S-J. Modification of sample size in group sequential clinical trials. Biometrics 1999;55 853-857. (Pubitemid 29427088)